Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.